Compare Amplify Transformational Data Sharing ETF (BLOK) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs Quest Diagnostics Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $61.14, while Quest Diagnostics Inc trades at $205.45 (market cap $22.95B). The key difference: Quest Diagnostics Inc pays a 1.66% dividend while Amplify Transformational Data Sharing ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| BLOK | DGX | |
|---|---|---|
52-Week High | $74.10 | $216.02 |
52-Week Low | $47.36 | $166.42 |
Market Cap | — | $22.95B |
Sector | — | Health |
Enterprise Value | — | $28.97B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.81, down 2.95% on the day, with a bearish technical signal from moving averages while oscillators are neutral. The stock faces resistance near $62 and support at $60. Recent news highlights its diversified blockchain economy exposure, including miners and enterprise adopters, though financial ratios like P/E and P/S are not provided in the current dataset.
The outlook remains cautious due to technical bearishness and increased reliance on Bitcoin performance, posing volatility risks. Investment opportunity lies in broad blockchain sector exposure, but risks include market sentiment shifts and lack of near-term catalysts, warranting close monitoring of earnings and sector trends.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
